AI Article Synopsis
Article Abstract
How to identify haloperidol and tiapride in the urine by thin layer chromatography was proposed. Optimal systems of solvents were selected by chromatographic mobility of the substances studied in 14 solvents with different polarity. The findings allowed making an optimal choice of the composition and proportion of the solvents. Diethylamine, as a basic modifier, was introduced in the system of solvents. This improved chromatographic mobility of haloperidol and tiapride. Optimal mobile phases, developers were found, the threshold of detectability of the substances in the given conditions was established. The techniques were used for identification of haloperidol and tiapride in the samples from model urine mixture in the presence of non-identified endogenic compounds. They are characterized by rapid performance, selectivity, sensitivity and good reproducibility and can be introduced into practice of chemicotoxicological laboratories.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Objective: This study estimated delirium incidence in Slovak COVID-19 patients, explored treatment associations and examined the impact on hospitalization and mortality.
Background: The COVID-19 pandemic caused by SARS-CoV-2 has significantly affected global health. Delirium, a severe form of acute brain dysfunction, is common in hospitalized patients, including those with COVID-19.
Antipsychotic prescribing practices in real-life (APPREAL study): Findings from the French National Healthcare System Database (2007-2017).
Front Psychiatry
October 2022
PELyon, Lyon, France.
Background: Antipsychotics are used in a large variety of psychiatric and neurological disorders; investigating their use in real life is important to understand national prescribing practices, as well as to determine the levels of patient adherence.
Methods: Using a 1/97e random sample (General Sample of Beneficiaries, EGB) of the French health insurance reimbursement database, we conducted a historical cohort study on the 2007-2017 period. The aim was to describe the sociodemographic characteristics of patients, the types of antipsychotics dispensed, the types of prescribers, the mean doses and average durations of treatment, the co-dispensed medications, and the levels of adherence to treatment.
Treatment-resistant diabetic chorea manifesting with psychiatric symptoms: a case report.
Neurocase
October 2022
Department of Neurology, Saiseikai Utsunomiya Hospital, Utsunomiya-city, Tochigi, Japan.
We report a case of a 69-year-old man with treatment-resistant diabetic chorea presenting psychiatric symptoms. The right chorea lasted for 3 months and was refractory to control of diabetes mellitus or administration of haloperidol and benzodiazepines. Only administration of tiapride was efficacious.
View Article and Find Full Text PDFMedication Choices in Children With Tic Disorders in Mainland China, Macao, Hong Kong, and Taiwan: Perspectives of Guardians and Physicians.
Front Pharmacol
May 2022
Department of Health Policy and Management, West China School of Public Health/West China Fourth Hospital, Sichuan University, Chengdu, China.
Survey pediatricians and guardians of children with tic disorder on medication needs and choices. We designed a cross-sectional survey for pediatricians in mainland China, Hong Kong, Macao, and Taiwan, as well as for the guardians of patients with tic disorder from West China Second University Hospital. We collected and analyzed information on clinicians' medical behavior and medication choices and on guardians' knowledge of tic disorder, medical treatment behaviors, and medication choices and needs.
View Article and Find Full Text PDFEuropean clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Eur Child Adolesc Psychiatry
March 2022
Division of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Article Synopsis
- In 2011, the European Society for the Study of Tourette Syndrome released the first guidelines for treating Tourette Syndrome, which have been updated to reflect new research and expert survey results.
- The updated guidelines emphasize the importance of psychoeducation and behavioral therapies for enhancing patient autonomy, but recognize that pharmacological treatment is often necessary for many patients.
- Aripiprazole is recommended as the first-choice medication due to its better side-effect profile, with other possible treatments like tiapride, risperidone, and clonidine considered based on individual patient needs and conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!